Market news

BOSTON, September 29, 2026--Ginkgo Datapoints and Apheris welcome AbbVie, argenx, Lundbeck, and Takeda as Founding Members of the Antibody Developability Consortium

Sept 18 () - Dr ‌Reddy's ‌Laboratories said ​on Friday it signed ‌a ⁠deal with ⁠Takeda Pharmaceutical ​Company ​for ​the ‌promotion and distribution of the ‌Qdenga ​dengue ​vaccine ​in ‌India. (Reporting by ​Kashish ​Tandon in ​Bengaluru; ‌Editing by ​Sonia ​Cheema).

Takeda Pharmaceutical Company Limited (NYSE:TAK) announced on September 14 that the FDA accepted its New Drug Application for zasocitinib under priority review for adults with moderate-to-severe plaque psoriasis. The target action date falls in the first quarter of calendar 2027, creating a defined regulatory window for the investigational once-daily oral treatment. Zasocitinib inhibits tyrosine kinase […]

MALMO, Sweden & WILMINGTON, Del., September 09, 2026--Trialbee, the global patient recruitment leader reimagining clinical trials with AI, will present alongside Takeda at DPHARM 2026 taking place September 15–16 in Boston.

Andrew Stewart Plump, Director, President, Research and Development, on September 02, 2026, sold 116

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Complement Inhibitors Market Complement Inhibitors Market Dublin, Sept. 02, 2026 (GLOBE NEWSWIRE) -- The "Complement Inhibitors Market (2nd Edition): Distribution by Target Disease Indication, Therapeutic Area, Type of Molecule, Target Pathway, Type of Therapy, Route of Administration, Leading Drugs, Key Geographical Regions and Leading Players - Trends and Forecast Till 2035" has been added to ResearchAndMarkets.com's offering. The global complement inhibitors market is projected to increase fr

The joint effort began with AI-assisted IND submission preparation and has since expanded to HAQ and RTQ processes.

SAN FRANCISCO, September 01, 2026--Weave Bio, the leader in AI-native regulatory automation for drug development, today announced a collaboration with Takeda to deploy the Weave platform across 14 active programs in multiple global markets. The collaboration brings together Weave's AI capabilities and Takeda's regulatory expertise to support innovation in regulatory workflows.

Protagonist Therapeutics recently reported that the U.S. FDA approved MIMRYLO (rusfertide), the first hepcidin mimetic peptide therapy for adults with polycythemia vera, a rare blood cancer. This regulatory milestone also activates milestone payments from partner Takeda, underlining how MIMRYLO’s unique mechanism could reshape treatment options in this indication. We’ll now examine how FDA approval of MIMRYLO and the associated Takeda milestone payments influence Protagonist Therapeutics’...

On Friday, the U.S. Food and Drug Administration (FDA) approved Takeda Pharmaceutical Co. Ltd.‘s (NYSE:TAK) MIMRYLO (rusfertide) for polycythemia vera, a type of blood cancer. How MIMRYLO Combats Polycythemia Vera Polycythemia vera forces the human body to overproduce red blood cells. This harmful overproduction dramatically increases blood thickness. Increased viscosity places patients at high risk for life-threatening thrombotic events, which include severe complications like strokes, pulmonar

The clearance and broader-than-expected label for Mimrylo open up a yearly revenue opportunity for Takeda that some analysts expect to reach $2 billion or more.

OSAKA, Japan & CAMBRIDGE, Mass., August 28, 2026--Takeda (TSE:4502/NYSE:TAK) announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer.

Keros gets a $20M Takeda milestone, boosting cash and flexibility, but weak revenue visibility keeps collaboration income in focus.

The drug is the first to address one of the root causes of the sleeping disorder.

The consensus price target hints at a 26.4% upside potential for Takeda Pharmaceutical Co. (TAK). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

On July 30, Keros Therapeutics, Inc. (NASDAQ:KROS) triggered a $20 million development milestone payment from its global partner Takeda Pharmaceutical Company Limited (NYSE:TAK). The payout followed the first patient dosed in the Phase 3 ELRiSE MDS clinical trial, evaluating elritercept against epoetin alfa for anemia caused by low-to-intermediate-risk myelodysplastic syndromes. Under their January 2025 global […]

Takeda secured FDA approval for ORZEYFUL, a first-in-class oral orexin treatment for adults with narcolepsy type 1.

GlobalData analysts previously flagged Orzeyful’s approval as a key Q3 catalyst for the pharma industry due to the drug’s ‘transformative’ potential.

Jab recently approved for disease that infected 120,000 people last year

LEXINGTON, Mass., July 30, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today announced that it will receive a $20 million development milestone payment under the terms of the license agreement of elriter

Takeda Pharmaceutical (NYSE:TAK) said its first-quarter fiscal 2026 results were in line with its full-year outlook as growth from core brands and newer products largely offset expected declines in its mature portfolio. Revenue totaled JPY 1.22 trillion, up 10.2% on an actual foreign-exchange basis

In July 2026, Takeda announced new Phase 3 data for its oral TYK2 inhibitor zasocitinib (TAK-279) in adults with moderate-to-severe plaque psoriasis, showing consistently high rates of skin clearance across difficult areas such as the scalp, nails, palms and soles compared with placebo. The data highlight zasocitinib’s highly selective TYK2 inhibition as a potential way to tackle immune-mediated inflammation while aiming to limit safety issues associated with broader JAK inhibition. We’ll...

Takeda Pharmaceutical (TSE:4502) has drawn fresh investor attention after presenting new Phase 3 data for its oral TYK2 inhibitor zasocitinib in moderate to severe plaque psoriasis at the AAD Innovation Academy. See our latest analysis for Takeda Pharmaceutical. The zasocitinib update lands as Takeda Pharmaceutical’s momentum has been picking up, with a 30 day share price return of 11.75% and a year to date share price return of 14.89%. The 1 year total shareholder return of 35.86% and 5 year...

Takeda Pharmaceutical stock has delivered a strong 91.4% return over the past 5 years, and with the latest valuation checks suggesting the shares screen as undervalued on market multiples, investors are weighing how much of the story is already reflected in the price. Over 5 years, Takeda Pharmaceutical has returned 91.4%, which puts the recent share performance firmly in focus when judging whether the current valuation still leaves room for further upside. Recent news on zasocitinib Phase 3...

Takeda Pharmaceutical (TSE:4502) agreed a multi-year collaboration with the Indonesian Government to develop the country's plasma collection and biopharmaceutical manufacturing ecosystem. The company also reported Phase 3 data for its TYK2 inhibitor zasocitinib in plaque psoriasis, with trial results showing consistent and high skin clearance rates in difficult to treat patients. For investors following large global drug companies, Takeda Pharmaceutical sits at the intersection of specialty...

Takeda Pharmaceutical (TSE:4502) agreed a multi-year collaboration with the Indonesian Government to develop the country's plasma collection and biopharmaceutical manufacturing ecosystem. The company also reported Phase 3 data for its TYK2 inhibitor zasocitinib in plaque psoriasis, with trial results showing consistent and high skin clearance rates in difficult to treat patients. For investors following large global drug companies, Takeda Pharmaceutical sits at the intersection of specialty...

Takeda today announced that India's Drug Controller General of India (DCGI) has granted marketing authorization for Takeda's dengue vaccine (TAK-003) for the prevention of dengue disease in individuals 4 (four) to 60 (sixty) years of age. TAK-003 is India's first-ever approved dengue vaccine and was approved for use in individuals regardless of previous dengue exposure, without the need for pre-vaccination testing.

South Asian country grapples with sharp rise in cases over recent years

Takeda plans to invest up to $30m to begin establishing an ecosystem for PDMPs and a plasma donation pilot.

Insilico Medicine said Thursday it entered into a strategic collaboration with Takeda Pharmaceutical Co. Ltd. to use its proprietary Pharma.AI platform to discover and advance new drug candidates across multiple therapeutic areas. Deal Includes Upfront Payments And Future Milestones As...